Welcome to PrEP Watch, a clearinghouse for information on pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP Watch includes information on data, additional research, cost, access and advocacy efforts in the United States and across the globe.

Resources to Understand PrEP

PrEP is a new and emerging HIV prevention intervention in which HIV-negative individuals take an antiretroviral (ARV) to reduce their individual risk of acquiring HIV. More here.

PrEP Data to-Date

A number of large-scale trials from a range of populations and in different areas of the world have generated data showing that daily oral TDF/FTC (Truvada) is safe and effective to reduce the risk of HIV infection for HIV-negative people. More here.


Guidelines for prescribing and using PrEP are available from a range of groups, including state health departments in the US, the US Centers for Disease Control (CDC) and national-level clinician groups as well as guidelines on international demonstration projects from the World Health Organization. More here.

Implementing PrEP in the “Real World”

Depending on location, communities are at varying stages of implementing PrEP. In the US the Food and Drug Administration (FDA) has approved daily Truvada for HIV prevention, and some communities in the US are exploring how it might best be delivered. Outside of the US, Truvada as PrEP is not approved by local regulators and in most cases remains inaccessible outside of research studies. Country-specific information is being collected. More here.

Cost, Access and Using PrEP

There is a growing body of information on how to access PrEP and how its cost can be covered in the US. There is limited access elsewhere outside of clinical trials or demonstration projects. More here.

Ongoing research

At the same time, additional clinical trial research is ongoing to test new regimens—twice-weekly, for example—and different ARVs, like maraviroc. More here.

Local Advocacy

Advocacy efforts supporting both the PrEP research pipeline and PrEP access for populations most in need are active in areas around the world. More here

Other HIV Prevention Research

PrEP is just one element of the ARV-based and wider biomedical HIV prevention agenda, which include a range of proven approaches and others under study. More here.

Quick Links

What’s new

PrEP Implementation Science: State-of-the-Art and Research Agenda

Published by the Journal of the International AIDS Society, this special issue addresses a wide-range of concerns surrounding oral PrEP. The six articles examine the importance of PrEP within a wider HIV prevention structure, while also discussing concerns related to implementation, cost-effectiveness, ethics and access.

PrEP for MSM Cannot Wait

MSMGF calls for the widespread availability and access to PrEP as an integral part of a comprehensive sexual health program for men who have sex with men (MSM).

HIV Prevention Pill Test Begins in Amsterdam Gay, Transgender Community

The study will focus on the interest to use Prep, compliance on taking the pill, how it is to use Prep and whether the cost of this program outweigh the costs saved by preventing people from becoming infected with HIV.

Kuehl’s LA County-Wide PrEP Proposal Passes

The LA County Board of Supervisors passed a proposal to provide PrEP county-wide.

South African AIDS Activists Demand PrEP NOW

As the 7th SA AIDS conference gets underway in Durban, a diverse collection of advocates have assembled to call on the South African Medicines Control Council (MCC) to immediately approve the use of Truvada PrEP.

Kuehl to Introduce Motion to Distribute PrEP Throughout L.A. County

Los Angeles County Supervisor Sheila Kuehl will introduce a motion that calls for “a robust, comprehensive program to deliver Pre‑Exposure Prophylaxis (PrEP) throughout the County.” The CDC endorsed PrEP as an HIV prevention strategy and issued clinical guidelines last year.